Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.44 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050740 | 0.91 | PTGS2 (0.61) | PTGS2PTGS1ESR1KDM4EMT-CO1 | |
| SCHEMBL6050699 | 0.87 | PTGS2 (0.60) | PTGS2PTGS1ESR1KDM4EHPGD | |
| SCHEMBL6050619 | 0.87 | PTGS2 (0.60) | PTGS2PTGS1ESR1KDM4EHPGD | |
| SCHEMBL6050737 | 0.86 | PTGS2 (0.56) | PTGS2PTGS1ESR1KDM4EMT-CO1 | |
| SCHEMBL6050867 | 0.83 | PTGS2 (0.56) | PTGS2PTGS1ESR1KDM4EMT-CO1 | |
| SCHEMBL6050765 | 0.81 | IKBKB (0.46) | PTGS2PTGS1IKBKBKDM4EHPGD | |
| SCHEMBL6050848 | 0.81 | IKBKB (0.46) | PTGS2PTGS1IKBKBKDM4EHPGD | |
| SCHEMBL7869531 | 0.81 | PTGS2 (0.53) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL6050686 | 0.80 | PTGS2 (0.52) | PTGS2PTGS1ESR1KDM4EMT-CO1 | |
| SCHEMBL6050692 | 0.80 | PTGS2 (0.52) | PTGS2PTGS1ESR1KDM4EMT-CO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030153-B2 | 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents | G.D. SEARLE & CO. (US) | 2006-04-18 | — | — | US | disclosed |
| US-7012094-B1 | Substituted furans and furanones for the treatment of inflammation | G.D. SEARLE, LLC (US) | 2006-03-14 | — | — | US | disclosed |
| US-20030153602-A1 | 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents | G.D. SEARLE & CO. (US) | 2003-08-14 | — | — | US | disclosed |
| US-6599934-B1 | Effective and safe compounds having antiinflammatory and/or analgesic activity without erosion of the stomach | G.D. SEARLE & CO. | 2003-07-29 | — | — | US | disclosed |
| US-20030013744-A1 | 3,4-diaryl thiophenes and analogs thereof having use as anti-inflammatory agents | G.D. SEARLE & CO. (US) | 2003-01-16 | — | — | US | disclosed |
| US-6492413-B2 | FOR USE IN THERAPY OF PAIN, ARTHRITIS, FEVER | G.D. SEARLE & CO. | 2002-12-10 | — | — | US | disclosed |
| US-20020058691-A1 | 3,4-Diaryl Thiophenes and analogs thereof having use as antiflammatory agents | TALLEY JOHN J (US) | 2002-05-16 | — | — | US | disclosed |
| US-6274590-B1 | ADMINISTERING 3,4-DIARYLTHIOPHENE DERIVATIVE TO TREAT ECZEMA, BURNS, PSORIASIS, AND DERMATITIS | G. D. SEARLE & CO. | 2001-08-14 | — | — | US | disclosed |
| EP-0679157-B1 | NOVEL 3,4-DIARYL THIOPHENES AND ANALOGS THEREOF HAVING USE AS ANTIINFLAMMATORY AGENTS | SEARLE & CO (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0679157-A1 | NOVEL 3,4-DIARYL THIOPHENES AND ANALOGS THEREOF HAVING USE AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1995-11-02 | — | — | EP | disclosed |
| WO-1994015932-A1 | NOVEL 3,4-DIARYL THIOPHENES AND ANALOGS THEREOF HAVING USE AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013744-A1 | 3,4-diaryl thiophenes and analogs thereof having use as anti-inflammatory agents | NR3C1, FPR1, IL1B | PTGS2 151/4885PTGS1 17/4885ESR1 2801/4885 |
| US-20020058691-A1 | 3,4-Diaryl Thiophenes and analogs thereof having use as antiflammatory agents | NR3C1, FPR1, NR4A1 | PTGS2 156/4885PTGS1 5/4885ESR1 3883/4885 |
| US-20030153602-A1 | 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents | NR3C1, FPR1, NR3C2 | PTGS2 138/4885PTGS1 17/4885ESR1 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.